High-Sensitivity Troponin T for Acute MI Diagnosis & Cardiac Risk Stratification
The Sekbio Cardiac Troponin T (cTnT) Antibody Pair enables high-sensitivity quantification of cardiac Troponin T — the cardiac-specific structural protein released into the bloodstream following cardiomyocyte injury. Along with cTnI, cTnT is the internationally preferred biomarker for AMI diagnosis, with high-sensitivity assays enabling the 0h/1h or 0h/2h rapid AMI rule-out/rule-in algorithms endorsed by the European Society of Cardiology.
Designed for the CLIA chemiluminescence platform, the antibody pair achieves an analytical LoD of 0.003 ng/mL — entering the high-sensitivity troponin performance range where 99th percentile URL (upper reference limit) quantification in healthy populations becomes feasible. CV ≤10% precision meets the recommended ≤10% imprecision criterion at the 99th percentile URL.
Analytical LoD of 0.003 ng/mL places this assay in the high-sensitivity troponin category — enabling 99th percentile URL measurement in healthy reference populations and supporting ESC 0h/1h rapid AMI protocols.
High-sensitivity cTnT enables the ESC-recommended 0h/1h and 0h/2h rapid rule-out strategies — where a low absolute value at 0h plus minimal rise at 1h has >99% NPV for AMI rule-out.
CV ≤10% at the 99th percentile URL (typically 14–19 ng/L for hsTnT) meets the universal guideline requirement for high-sensitivity troponin assays — enabling reliable serial delta-change calculation.
0.003–3.0 ng/mL covers the full clinical spectrum: undetectable healthy baseline through massive STEMI elevations — without requiring manual dilution for peak troponin measurement in most presentations.
Antibody pair developed against cardiac-specific epitopes of TnT not shared with skeletal muscle TnT isoforms — preventing false positives from exercise, rhabdomyolysis, or polymyositis.
Anti-cTnT sandwich pair available as OEM bulk reagent for CLIA analyzer integration. Method comparison data and precision data package available for regulatory submissions.
| Parameter | Value | Notes |
|---|---|---|
| Analytical LoD | 0.003 ng/mL | Blank mean + 3SD, n=20 replicates |
| Detection Range | 0.003 – 3.0 ng/mL | Verified by serial dilution linearity |
| CV at Low QC | ≤ 10% | At 99th percentile URL level |
| CV at Mid QC | ≤ 7% | Within-run, n=10 replicates |
| High-Sensitivity Classification | ≥ 50% detectable in healthy reference | Meets IFCC high-sensitivity definition |
| Performance category: high-sensitivity cTnT. Full calibration data and lot certificates available on request. | ||
| Decision Zone | cTnT Criterion | Clinical Action |
|---|---|---|
| Rule-Out (0h) | cTnT < LoD and low clinical probability | Discharge consideration (NPV >99%) |
| Rule-Out (0h+1h) | Low 0h value + delta <3 ng/L at 1h | Rapid rule-out with >99% NPV |
| Rule-In (0h) | cTnT > 52 ng/L (×5 URL) | High probability AMI — urgent cardiology |
| Observe Zone | Intermediate values or delta >3 ng/L | 3h/6h serial sampling required |
| Based on ESC 2020 NSTE-ACS guideline 0h/1h algorithm using hsTnT. Institutional cut-offs may vary. | ||
hsTnT supports ESC 0h/1h rapid AMI protocols in the emergency department — reducing hospitalization for low-risk chest pain patients while ensuring fast identification of true AMI.
Serial cTnT measurement for peri-operative myocardial injury (PMI) detection after cardiac and non-cardiac surgery. Sensitive assay detects sub-clinical myocardial injury affecting post-op prognosis.
Chronically elevated hsTnT is independently associated with worse outcomes in heart failure. Baseline and serial cTnT measurements guide risk stratification and treatment intensity in HF patients.
Anti-cTnT monoclonal pair for CLIA analyzer integration. Full performance package — LoD, precision, linearity, method comparison — for regulatory submissions and OEM analyzer qualification.
Technical datasheets, performance data, and OEM supply details available on request.